Travere Therapeutics (TVTX) drew increased attention after reporting second quarter 2026 results, with revenue of US$169.58 million and a wider net loss of US$34.8 million as FILSPARI uptake expanded.

At a share price of US$62.45, Travere Therapeutics has seen strong momentum build, with a 90 day share price return of 46.6% and a one year total shareholder return of 269.31% that reflects changing expectations around its rare kidney portfolio.

If Travere’s recent move has you rethinking your watchlist, it could be a good moment to broaden your search and check out 20 top founder-led companies

Bulls point to Travere Therapeutics’ rare kidney lead and FILSPARI traction, while bears focus on the ongoing net losses and execution risk. Which side does the current share price and valuation evidence support?

Most Popular Narrative: 8.6% Undervalued

Travere Therapeutics is trading at $62.45 compared with a narrative fair value of $68.36, which frames the recent share price surge through a valuation lens.

Expansion of FILSPARI's label to include treatment for FSGS, a rare kidney disease with no approved therapies, positions Travere for first-mover advantage in a large, underserved market. If approved, this could create a new, high-margin revenue stream and significantly expand the company's addressable market. (Revenue growth, gross margins)

Want to understand why this fair value sits above today’s price? The narrative focuses on rapid top line expansion, sharply higher margins and a richer future earnings multiple. The full story links those elements into one valuation framework.

Result: Fair Value of $68.36 (UNDERVALUED)

However, the Travere Therapeutics narrative still hinges on FILSPARI concentration and regulatory outcomes, so setbacks on approvals or new competitors could quickly challenge today’s optimism.

Next Steps

With all this optimism around Travere Therapeutics, it helps to pressure test the story against the actual data and risks. Take a closer look at the company’s potential rewards through 3 key rewards

Looking for more investment ideas beyond Travere Therapeutics?

If Travere Therapeutics has sharpened your interest in focused opportunities, do not stop here. Use the Simply Wall St screener to spot clear ideas that match your style.

• Tap into potential mispricing by checking 51 high quality undervalued stocks that combine quality fundamentals with attractive valuations.
• Prioritise resilience by scanning 78 resilient stocks with low risk scores built around companies with lower risk scores.
• Get ahead of the crowd by searching through the screener containing 19 high quality undiscovered gems before they land on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.